Fonidel™

Fondaparinux Sodium
Anticoagulant (Cardiovascular Preparations)

Indication:

– Management of ACS (Acute Coronary Syndrome)
– Treatment of Deep Vein Thrombosis (DVT) or acute Pulmonary Embolism (PE) when administered in conjunction with warfarin
– Prophylaxis of DVT in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery or abdominal surgery

Dosage & Administration:

Management of ACS (Acute Coronary Syndrome): Fondaparinux Sodium 2.5 mg subcutaneously once daily for the duration of hospitalization or until PCI is performed.

Prophylaxis of deep vein thrombosis: Fondaparinux Sodium 2.5 mg subcutaneously once daily for 5 to 9 days. For patients undergoing hip fracture surgery, extended prophylaxis up to 24 additional days is recommended.

Treatment of deep vein thrombosis and pulmonary embolism: Fondaparinux Sodium 5 mg (body weight <50 kg), 7.5 mg (50 to 100 kg) or 10 mg (>100 kg) subcutaneously once daily. Treatment should be continued for at least 5 days until INR 2 to 3 achieved with warfarin sodium.

Preparation:

Fonidel^™ 2.5 PFS: Each box contains 1 pre-filled syringe (containing 2.5 mg Fondaparinux sodium) in blister pack.